Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice

A Boireau1, F Bordier, P Dubédat

  • 1Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.

Neuroscience Letters
|November 19, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of repetitive open sea dives and physical exercises on right-to-left shunting in healthy divers.

British journal of sports medicine·2007
Same author

RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz.

Bioorganic & medicinal chemistry letters·2001
Same author

Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.

Bioorganic & medicinal chemistry letters·2001
Same author

Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

Behavioural brain research·2001
Same author

Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.

Bioorganic & medicinal chemistry letters·2001
Same journal

DAla2-GIP-Glu-PAL exerts neuroprotective effect on diabetic retinopathy by attenuating microglia activation and regulating NF-κB/NLRP3 and Nrf2/HO-1 pathways.

Neuroscience letters·2026
Same journal

Dynorphinergic neuroadaptations in the islands of Calleja: implications for alcohol use disorder.

Neuroscience letters·2026
Same journal

Differential vulnerability of cochlear nuclei to Lmx1 deficiency: abnormal patterning and implications for auditory circuitry.

Neuroscience letters·2026
Same journal

Role of nNOS/sGC pathway in the insular cortex in control of cardiovascular, autonomic and corticosterone responses to restraint stress in rats.

Neuroscience letters·2026
Same journal

Jak1 inhibition reduces acute allodynia induced by specific upstream cytokines in rats: implications for the onset of Jak1 pain modulation.

Neuroscience letters·2026
Same journal

Glucocorticoids-induced depressive-like behaviors in mice: oral ingestion of corticosterone or hydrocortisone - A comparative study.

Neuroscience letters·2026
See all related articles

Thalidomide protected against MPTP-induced dopamine loss in a Parkinson's disease mouse model. This suggests inflammation plays a role in neurodegeneration, offering potential therapeutic insights.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Parkinson's disease is a neurodegenerative disorder characterized by dopamine neuron loss.
  • MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to model Parkinson's disease in mice.
  • Inflammation is increasingly recognized as a contributing factor in neurodegenerative diseases.

Purpose of the Study:

  • To investigate the neuroprotective effects of thalidomide in the MPTP mouse model of Parkinson's disease.
  • To determine if thalidomide modulates dopamine and its metabolites in the striatum of MPTP-treated mice.
  • To explore the potential involvement of inflammatory processes in MPTP-induced neurotoxicity.

Main Methods:

  • MPTP murine model of Parkinson's disease was established.
  • Mice received thalidomide at 25 mg/kg or 50 mg/kg postoperatively.

Related Experiment Videos

  • Striatal levels of dopamine (DA), DOPAC, and HVA were measured using biochemical assays.
  • MPTP control group received vehicle treatment.

    • Main Results:

    • Thalidomide demonstrated dose-dependent protection against MPTP-induced decrease in striatal dopamine (DA).
    • Thalidomide completely antagonized the reduction in homovanillic acid (HVA) levels at both tested doses.
    • MPTP treatment significantly reduced DA and HVA levels compared to controls.

    Conclusions:

    • Thalidomide exhibits neuroprotective effects in the MPTP mouse model, suggesting a therapeutic potential.
    • The findings support the hypothesis that inflammatory mechanisms are involved in MPTP-induced dopaminergic neurotoxicity.
    • Thalidomide's anti-inflammatory properties may underlie its observed protective effects.